TA134: Psoriasis - infliximab
This is a discussion on TA134: Psoriasis - infliximab within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Psoriasis - infliximab. It links to the published guidance and key documents. More......
|
|||||||
| Register | Help | Members List | Mark Forums Read |
04-01-2010, 12:51 PM
|
|||
|
|||
TA134: Psoriasis - infliximab
The summary for the published technology appraisal on Psoriasis - infliximab. It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA103: Psoriasis - efalizumab and etanercept | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA146: Psoriasis - adalimumab | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA180: Psoriasis - ustekinumab | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA180: Psoriasis - ustekinumab | industry_news | Updates from the Technology Assessment Authorities | 0 | 09-22-2009 08:06 PM |
| AAD releases new guidelines for the management of psoriasis | chantell.reagan | Other Clinical Pharmacy News | 0 | 06-09-2009 04:35 PM |
© 2008 DrugManagementForum™ powered by |
 |